Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas H Claus

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Journal of the American Medical Directors Association|January 27, 2011
Severe Alzheimer's disease: treatment effects on function and care requirementsDiana Kerwin, Thomas H Claus
Journal of the American Medical Directors Association|July 22, 2018
ReplyDiana R Kerwin, Thomas H Claus
The Journal of Pharmacology and Experimental Therapeutics|September 16, 2005
Specific inhibition of hormone-sensitive lipase improves lipid profile while reducing plasma glucoseThomas H Claus, Derek B Lowe, Yin Liang, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 3, 2007
A novel long-acting selective neuropeptide Y2 receptor polyethylene glycol-conjugated peptide agonist reduces food intake and body weight and improves glucose metabolism in rodentsAstrid A Ortiz, Lucinda F Milardo, Lynn B DeCarr, et al.
The Journal of Biological Chemistry|March 1, 2006
Design of a long acting peptide functioning as both a glucagon-like peptide-1 receptor agonist and a glucagon receptor antagonistClark Q Pan, Joanne M Buxton, Stephanie L Yung, et al.
Journal of Medicinal Chemistry|December 8, 2006
Engineering of a VPAC2 receptor peptide agonist to impart dipeptidyl peptidase IV stability and enhance in vivo glucose disposalKevin B Clairmont, Thomas M Buckholz, Carla M Pellegrino, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 18, 2006
Engineering novel VPAC2-selective agonists with improved stability and glucose-lowering activity in vivoClark Q Pan, Fugang Li, Irene Tom, et al.
Diabetes|April 30, 2002
A potent and highly selective VPAC2 agonist enhances glucose-induced insulin release and glucose disposal: a potential therapy for type 2 diabetesManami Tsutsumi, Thomas H Claus, Yin Liang, et al.
The Journal of Endocrinology|February 7, 2007
Dual-acting peptide with prolonged glucagon-like peptide-1 receptor agonist and glucagon receptor antagonist activity for the treatment of type 2 diabetesThomas H Claus, Clark Q Pan, Joanne M Buxton, et al.
Endocrinology|July 28, 2007
Small-molecule ghrelin receptor antagonists improve glucose tolerance, suppress appetite, and promote weight lossWilliam P Esler, Joachim Rudolph, Thomas H Claus, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Journal of the American Medical Directors Association|January 27, 2011
Severe Alzheimer's disease: treatment effects on function and care requirementsDiana Kerwin, Thomas H Claus
Journal of the American Medical Directors Association|July 22, 2018
ReplyDiana R Kerwin, Thomas H Claus
The Journal of Pharmacology and Experimental Therapeutics|September 16, 2005
Specific inhibition of hormone-sensitive lipase improves lipid profile while reducing plasma glucoseThomas H Claus, Derek B Lowe, Yin Liang, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 3, 2007
A novel long-acting selective neuropeptide Y2 receptor polyethylene glycol-conjugated peptide agonist reduces food intake and body weight and improves glucose metabolism in rodentsAstrid A Ortiz, Lucinda F Milardo, Lynn B DeCarr, et al.
The Journal of Biological Chemistry|March 1, 2006
Design of a long acting peptide functioning as both a glucagon-like peptide-1 receptor agonist and a glucagon receptor antagonistClark Q Pan, Joanne M Buxton, Stephanie L Yung, et al.
Journal of Medicinal Chemistry|December 8, 2006
Engineering of a VPAC2 receptor peptide agonist to impart dipeptidyl peptidase IV stability and enhance in vivo glucose disposalKevin B Clairmont, Thomas M Buckholz, Carla M Pellegrino, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 18, 2006
Engineering novel VPAC2-selective agonists with improved stability and glucose-lowering activity in vivoClark Q Pan, Fugang Li, Irene Tom, et al.
Diabetes|April 30, 2002
A potent and highly selective VPAC2 agonist enhances glucose-induced insulin release and glucose disposal: a potential therapy for type 2 diabetesManami Tsutsumi, Thomas H Claus, Yin Liang, et al.
The Journal of Endocrinology|February 7, 2007
Dual-acting peptide with prolonged glucagon-like peptide-1 receptor agonist and glucagon receptor antagonist activity for the treatment of type 2 diabetesThomas H Claus, Clark Q Pan, Joanne M Buxton, et al.
Endocrinology|July 28, 2007
Small-molecule ghrelin receptor antagonists improve glucose tolerance, suppress appetite, and promote weight lossWilliam P Esler, Joachim Rudolph, Thomas H Claus, et al.
Pageof 2